BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins  University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | Jul 14, 2017

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
BC Innovations | Aug 4, 2016
Distillery Techniques

Techniques: Neurotensin (NTS)-based PET imaging agents for diagnosing and monitoring treatment responses of neurotensin receptor 1 (NTSR1)-positive tumors

Imaging TECHNOLOGY: PET Neurotensin-based PET imaging agents could help diagnose and monitor treatment-response for NTSR1-positive cancers. Two agents, consisting of a six-amino acid peptide derived from the N-terminus of neurotensin conjugated via linkers to a...
BC Innovations | Jun 16, 2016
Translation in Brief

Fat links

Although neurotensin promotes fat uptake, satiety and cancer cell growth, the hormone's instability has made it difficult to measure in the clinic or connect directly to human disease. Using an assay from sphingotec GmbH on...
BC Innovations | May 26, 2016
Distillery Therapeutics

Therapeutics: Neurotensin (NTS); neurotensin receptor 1 (NTSR1); proneurotensin

Endocrine/metabolic disease INDICATION: Obesity Human sample and mouse studies suggest inhibiting NTS- NTSR1 signaling could help treat obesity. In 4,632 obesity patients and healthy volunteers, high fasting plasma levels of the NTS precursor proneurotensin were...
BC Week In Review | Feb 29, 2016
Company News

Ipsen, 3B Pharmaceuticals deal

3B granted Ipsen exclusive, worldwide rights to develop and commercialize radiopharmaceuticals targeting the neurotensin (NTS) receptor. Ipsen will develop the preclinical compounds to treat pancreatic adenocarcinoma and potentially other cancers. 3B will receive an undisclosed...
BC Innovations | Dec 4, 2014
Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations to...
BC Innovations | Mar 13, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Neurotensin (NTS) In vitro and rodent studies suggest a conjugate of NTS and the brain-penetrating peptide Angiopep could help treat pain. In a mouse...
BC Week In Review | Mar 3, 2014
Clinical News

Angiochem preclinical data

In rat models of neuropathic and bone cancer pain, 0.05 mg/kg ANG2002 significantly reduced pain behaviors vs. vehicle-treated controls. Angiochem said ANG2002's analgesic efficacy was similar to that of morphine in a tail flick pain...
BC Week In Review | Dec 5, 2011
Company News

Affitech, IBC Generium deal

IBC Generium exercised a June option granting the company rights in the Commonwealth of Independent States to develop and commercialize Affitech's cancer candidate AT008 . Affitech received €2 million ($2.7 million). IBC Generium paid Affitech a...
Items per page:
1 - 10 of 23